





T Adverse events and survival with postpericardiotomy
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Tuomas O. Kiviniemi, MD, PhD, FESCa,gABSTRACT
Objectives: Postpericardiotomy syndrome (PPS) is a relatively common complica-
tion after cardiac surgery. However, long-term follow-up data on the adverse events
and mortality of PPS patients requiring invasive interventions are scarce.
Methods:We sought to assess the occurrence of mortality, new-onset atrial fibril-
lation (AF), cerebrovascular events, and major bleeds in PPS patients requiring
medical attention in a combination database of 671 patients who underwent iso-
lated surgical aortic valve replacement with a bioprosthesis (n¼ 361) or mechanical
prosthesis (n ¼ 310) between 2002 and 2014 (Cardiovascular Research Con-
sortium—A Prospective Project to Identify Biomarkers of Morbidity and Mortality
in Cardiovascular Interventional Patients [CAREBANK] 2016-2018). PPS was defined
as moderate if it resulted in delayed hospital discharge, readmission, or medical
therapy because of the symptoms; and severe if it required interventions for the
evacuation of pleural or pericardial effusion.
Results: The overall incidence of PPS was 11.2%. Median time to diagnosis was 16
(interquartile range, 11-36) days. Severe PPS was diagnosed in 3.6% of patients. Se-
vere PPS seemed to be associated with higher mortality (hazard ratio, 2.01; 95%
confidence interval, 1.03-3.91; P ¼ .040). Moderate or severe PPS increased the
risk of new-onset AF during the early postoperative period (hazard ratio, 1.72;
95% confidence interval, 1.12-2.63; P¼ .012). No significant associations were found
between PPS and cerebrovascular events or major bleeds during the follow-up.
Conclusions: Patients with PPS requiring invasive interventions are at increased
risk for mortality unlike those with mild to moderate forms of the disease. PPS
requiring medical attention is associated with a higher AF rate during the early post-
operative period but has no significant effect on the occurrence of major stroke,
stroke or transient ischemic attack, or major bleeds during long-term follow-up.
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Survival after isolated surgical aortic valve replacement
in patients with moderate postpericardiotomy syn-
drome (PPS; ie, PPS not requiring the evacuation of
pleural or pericardial effusion), patients with severe
PPS (ie, PPS requiring the evacuation of pleural or peri-
cardial effusion), and patients without PPS. Severe PPS
seemed to be associated with higher rates of mortality,
whereas patients with moderate PPS shared similar





Patients with severe PPS were at
increased risk for mortality. A tran-
sient increased risk of new-onset AF
was observed, but PPS had no effect
on theoccurrenceof cerebrovascular
events or major bleeds.PERSPECTIVE
There is a clinical need for more intensive follow-
up in patients with severe PPS. Severe PPS should
be considered as a separate end point in the
future clinical trials to identify the factors and
treatment methods that affect mortality and to
improve patient care and recovery.
See Commentaries on pages 1457 and 1458.ation; and an unrestricted grant from Bristol-Myers-
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9; available ahead of print Jan 28, 2020.
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AF ¼ atrial fibrillation
CI ¼ confidence interval
HR ¼ hazard ratio
NYHA ¼ New York Heart Association
PCI ¼ percutaneous coronary intervention
PPS ¼ postpericardiotomy syndrome
SAVR ¼ surgical aortic valve replacement
TIA ¼ transient ischemic attack
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Postpericardiotomy syndrome (PPS) is a relatively com-
mon complication after cardiac surgery.1 PPS is known
to cause prolonged hospital stay, readmissions, and inva-
sive interventions, including the evacuation of pleural
and/or pericardial effusion,2-6 but its prognosis is
considered to be benign.1 However, a recently published
large epidemiological study showed an association
between PPS and mortality during the first year after
the surgery,7 challenging the presumed benign nature of
the syndrome. Furthermore, it is unclear whether PPS is
associated with other postoperative adverse events that
could also mediate the higher mortality, such as new-
onset atrial fibrillation (AF), cerebrovascular events, and
major bleeding. The aim of this real-world study was to
evaluate the effect of PPS on late adverse events after
surgical aortic valve replacement (SAVR).METHODS
Data Collection
The present analysis includes patients from 2 separate databases included
in the Consortium Aiming at Reducing Adverse Outcomes Related to Atrial
Fibrillation in Patients Undergoing Cardiac Procedures (CAREFIB) Atrial
Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve
Implantation (CAREAVR); ClinicalTrials.gov identifier: NCT02626871
and the Cardiovascular Research Consortium—A Prospective Project to
Identify Biomarkers of Morbidity and Mortality in Cardiovascular
Interventional Patients (CAREBANK); ClinicalTrials.gov identifier:
NCT03444259. The consort diagram is outlined in Figure 1. The CAREFIB
Consortium is part of a broader ongoing protocol in Finland to evaluate
thromboembolic and bleeding complications related to AF management in
patients who undergo cardiac procedures.8,9
The CAREAVR is a Finnish multicenter retrospective study on the rate
of AF, thromboembolic complications, and bleeding events in patients who
undergo isolated bioprosthetic and mechanical SAVR. Clinical data on
consecutive patients who underwent isolated bioprosthetic SAVR were
retrieved from the cardiac surgery units of 3 Finnish university hospitalsThe Journal of Thoracic and Car(Turku, Oulu, and Kuopio) over the period of 2002 to 2014. Data on
consecutive patients who underwent isolated mechanical SAVR were
retrieved from Turku University Hospital during the same period. To obtain
reliable and accurate follow-up data, only patients from the hospitals’
catchment areas were included in this study. All major adverse events
including PPS, AF, cerebrovascular events, bleeding, and myocardial in-
farctions are treated almost exclusively in tertiary health care, and there-
fore, the patient follow-up for adverse events can be considered reliable.
An independent, certified third-party data monitor controlled the integrity
of the data at each study site.
The CAREBANK is an ongoing Finnish prospective cohort study on the
associations between the features of cardiac tissue samples and clinical
phenotypes in patients who undergo cardiac procedures. The present study
includes the consecutive patients from the CAREBANK study who under-
went isolated bioprosthetic or mechanical SAVR at the Turku University
Hospital from February 2016 to July 2018. As part of the study protocol,
data on all major adverse events including PPS, AF, cerebrovascular events,
and myocardial infarction are collected from the hospital records and by
follow-up phone calls at 3, 12, 24, and 60 months.
All patient records were individually reviewed using a standardized
structured data collection protocol for pre- and perioperative data,
discharge data, and long-term follow-up events. The end points of this pre-
specified study included the occurrence of PPS, postoperative AF during
index hospitalization and after discharge, major bleeding episodes, cere-
brovascular events, and death.
The causes of death were derived from Statistics Finland. This govern-
mental office monitors the time and causes of death in Finland. Personal
and immutable social security numbers are used to identify the patients.
Therefore, each case is carefully monitored even if the person moved.
During the study period, the routine anticoagulation practice was to
administer enoxaparin 40 to 60 mg subcutaneously once a day starting in
the evening of the day of the surgery and continuing until vitamin K antag-
onist treatment (started on the first postoperative day) reached the therapeu-
tic level (international normalized ratio2.0 or2.5). In the bioprosthetic
SAVR patients, anticoagulation with vitamin K antagonist up to 3 months
was a common practice (target international normalized ratio of 2.0-3.0).
PPS was defined by the presence of at least 2 of the following criteria:
(1) fever without alternative causes, (2) pericarditic or pleuritic chest pain,
(3) pericardial or pleural rubs, (4) evidence of pericardial effusion, and/or
(5) evidence of pleural effusion with elevated C-reactive protein level.10
The laboratory tests, imaging, and other examinations for differential diag-
nostics were executed as clinically indicated. Relapse was defined as wors-
ening pericardial or pleural effusion during treatment with medication or
after withdrawal of medication. PPS was categorized into 2 subgroups ac-
cording to the severity of the syndrome: moderate PPS that did not require
invasive intervention (ie, the evacuation of pleural or pericardial effusion),
and severe PPS requiring invasive interventions such as pericardial or
pleural drainage.
Diabetes, dyslipidemia, and hypertension were defined as a disease
requiring medical treatment and chronic lung disease as a pulmonary dis-
ease requiring the long-term use of bronchodilators or steroids. Peripheral
arterial disease was defined as 1 or more of the following: claudication, ca-
rotid artery disease of>50% diameter, and previous or planned interven-
tion on the abdominal aorta, limb arteries, or carotids. Heavy alcohol
consumption was defined as>14 doses a week for women and>21 doses
a week for men. Previous cardiac surgery was defined as 1 or more previous
major cardiac operation involving opening of the pericardium. Urgent
operation was defined as an operation performed during the index hospital
stay, emergency operation as an operation before the next working day, and
salvage procedure as an operation for which patients require cardiopulmo-
nary resuscitation en route to the operating theater or before the induction
of anesthesia. Major stroke was defined as a permanent focal neurological
deficit adjudicated by a neurologist and confirmed via computed tomogra-



































All patients undergoing an
open heart procedure from
February 2016 to July 2018
(n = 519) • Declination of participation (n = 22)
• Coronary artery bypass (n = 232)
• Mitral valve repair/replacement (n = 38)
• Ascending aortic procedure (n = 19)
• Descending aortic procedure (n = 5)
• Pericardiectomy (n = 3)
• Myxoma (n = 3)
• Procedure cancelled (n = 3)
• Tricuspid valve procedure (n = 1)
• Epicardial pacemaker implantation (n = 1)
• Combination procedure (n = 45)
• SAVR + concomitant procedure (n = 90)
• Missing data (n = 8)
Excluded (n = 470):
FIGURE 1. Study population consort diagram. CAREFIB, Consortium Aiming at Reducing Adverse Outcomes Related to Atrial Fibrillation in Patients
Undergoing Cardiac Procedures; CAREAVR, Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation; CAREBANK,
Cardiovascular Research Consortium—A Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients;
SAVR, surgical aortic valve replacement.




diameter). Transient ischemic attack (TIA) was defined as a transient
(<24 hours) focal neurological deficit adjudicated by a neurologist. The
combination end point stroke or TIA includes all ischemic strokes (lacunar
and major) combined to TIAs. Major bleed was defined as an overt, action-
able sign of hemorrhage that requires diagnostic studies, hospitalization, or
treatment by a health care professional (The Bleeding Academic Research
Consortium types 2-5).11
The study protocols were approved by theMedical Ethics Committee of
the Hospital District of Southwest Finland (numbers 8/1802/2014 and 65/
1801/2015 from the Ethical Committee of Hospital District of Southwest
Finland) and the ethics committee of the National Institute for Health
and Welfare (Finland). An informed consent was obtained from the partic-
ipants of the CAREBANK study. Because of the retrospective, observa-
tional nature of the CAREAVR study, an informed consent was not
required. The studies conform to the Declaration of Helsinki.
Statistical Analysis
Statistical analyses were conducted with R software version 3.5.3
(https://www.R-project.org). Continuous variables were reported as
mean  standard deviation if normally distributed and as median (25th-
75th percentiles) if skewed. The datawere tested for normal distribution us-
ing the Shapiro–Wilk test. Categorical variables were described as counts
and percentages. Cox proportional hazards model, unpaired t test, and
Mann–Whitney test were used for univariable analysis. The independency
of the predictors of PPS was evaluated using a Cox regression model with
interaction terms. The multivariable Cox regression models were per-
formed by including variables of relevance with a P value<.10 in the uni-
variable analyses in addition to the prosthesis type. Proportional hazards
assumption was assessed using graphical methods. Cause-specific
competing risk hazard models accounting for death were used for analyses1448 The Journal of Thoracic and Cardiovascular Surof outcomes other than mortality. Multiple testing correction was not
applied due to the explorative nature of the study.RESULTS
Incidence of PPS
A total of 671 patients underwent isolated SAVR at the
participating hospitals during the study period (bio-
prosthesis: n ¼ 361; mechanical prosthesis: n ¼ 310). The
median follow-up time was 9.0 (6.1-12.0) years for survival
and 5.1 (2.4-8.6) years for the other adverse events. Overall,
75 (11.2%) patients developed PPS leading to delayed hos-
pital discharge, readmission, or medical therapy because of
the symptoms. The median latency between the operation
and medical care contact was 16 (11-36) days. No PPS
developed after 188 postoperative days. PPS required the
evacuation of pleural effusion in 11 (14.7%), the evacuation
of pericardial effusion in 15 (20.0%) patients and led to car-
diac tamponade in seven (9.3%) patients. Thus, the inci-
dences of moderate and severe PPS were 51 (7.6%) and
24 (3.6%) patients of the total population, respectively.
The baseline characteristics and in-hospital events in pa-
tients with and without PPS are detailed in Table 1. No dif-
ferences were detected between the groups except that
patients with PPS were more often male, were more often
diagnosed with postoperative pneumonia, and underwentgery c December 2020
TABLE 1. Baseline characteristics and in-hospital events in patients with and without PPS
PPS (n ¼ 75) No PPS (n ¼ 596) P value
Age, y 72.0 [59.5-77.0] 70.0 [60.0-77.0] .89
Female sex 22 (29.3) 272 (45.6) .016
Diabetes 8 (10.7) 89 (15.0) .42
Dyslipidemia 42 (56.0) 276 (46.5) .13
Hypertension 55 (73.3) 403 (67.6) .35
Peripheral arterial disease 1 (1.3) 19 (3.2) .38
Coronary artery disease 21 (28.0) 144 (24.2) .52
Paroxysmal atrial fibrillation 7 (9.3) 62 (10.4) .58
Permanent atrial fibrillation 6 (8.0) 54 (9.1) .99
Chronic lung disease 10 (13.3) 83 (13.9) .97
Active smoking 7 (11.7) 58 (12.7) .80
Active or ex-smoker 26 (44.1) 171 (37.8) .33
Body mass index 26.7 [24.7-29.5] 27.5 [24.3-30.9] .76
Heavy alcohol consumption 4 (14.3) 22 (9.0) .39
Previous stroke 4 (5.3) 31 (5.2) .99
Previous myocardial infarction 6 (8.0) 27 (4.5) .36
Previous percutaneous coronary intervention 8 (10.7) 47 (7.9) .50
Previous cardiac surgery 2 (2.7) 37 (6.2) .32
Active endocarditis 3 (4.0) 28 (4.7) .88
Previous endocarditis 3 (4.0) 17 (2.9) .63
Previous venous thromboembolism 2 (2.7) 11 (1.8) .50
Pulmonary artery hypertension
Moderate to severe (systolic 31 mm Hg) 13 (23.6) 120 (29.0) .50
Severe (systolic>55 mm Hg) 3 (5.5) 21 (5.1) .75
NYHA class III or more 34 (45.3) 313 (52.5) .34
Preoperative eGFR (mL/min/1.73 m2) 76.0  22.4 77.0  20.5 .60
Urgent, emergency or salvage procedure 3 (4.0) 64 (10.7) .11
In-hospital events
New-onset atrial fibrillation* 27 (43.5) 192 (40.1) .64
Deep wound infection 1 (1.3) 4 (0.7) .50
Mediastinitis 0 (0.0) 5 (0.8) .99
Pneumonia 11 (14.7) 30 (5.0) <.001
Delayed ventilation 8 (10.8) 70 (11.8) .92
Acute de novo dialysis 1 (1.3) 7 (1.2) .78
Reoperation due to bleeding 9 (12.0) 53 (8.9) .30
Reoperation due to infection 1 (1.3) 3 (0.5) .34
Reoperation due to valve problem 2 (2.7) 5 (0.8) .045
Reoperation any 11 (14.7) 59 (9.9) .13
Length of hospital stay, d 8.0 [7.0-13.0] 8.0 [7.0-10.0] .20
Continuous variables are reported as median [interquartile range] or mean  standard deviation. Values in parentheses are percentages. PPS, Postpericardiotomy syndrome;
NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate. *Patients with preoperative paroxysmal or chronic atrial fibrillation excluded.






more often a reoperation because of a valve problem during
the index hospitalization. In a more detailed analysis, male
patients with PPS were significantly younger compared
with female patients with PPS (69.0 [55.0-75.0] years vs
77.5 [72.3-80.8] years; P ¼ .002). However, the sexThe Journal of Thoracic and Cardifference in PPS patients was not significantly modified
by age (Sex3Age groups interactionP¼ .49). In the multi-
variable model, male sex (hazard ratio [HR], 2.00; 95%
confidence interval [CI], 1.19-3.35; P ¼ .008) and pneu-
monia during the index hospitalization (HR, 2.43; 95%diovascular Surgery c Volume 160, Number 6 1449




CI, 1.26-4.72; P ¼ .008) remained as independent predic-
tors of PPS. No significant differences were detected in
the preoperative medications in patients with and without
PPS. Also, the comparison of moderate and severe PPS
showed no significant differences except that patients with
severe PPS presented more often with a history of preoper-
ative permanent AF (5 [20.8%] vs 1 [2.0%]; P¼ .001) and
heavy alcohol consumption (3 [33.3%] vs 1 [5.3%];
P ¼ .039). None of the patients with postoperative pneu-
monia and PPS were heavy alcohol users.
Treatment of PPS and Relapses
First-line medication for PPS was glucocorticoids in
64% of the patients, colchicine in 20% of the patients,
and nonsteroidal anti-inflammatory drugs in 5% of the pa-
tients. Overall 12 (16.0%) of the 75 patients with PPS had a
relapse defined by the worsening of pericardial or pleural
effusion during treatment with medication or after with-
drawal of the medication.
PPS and Mortality
The median follow-up time for mortality was 9.0 (6.1-
12.0) years and overall 206 deaths occurred during the
follow-up. The following were the variables of relevance
with a P value<.10 in the univariable analyses of mortality:
increasing age, female sex, diabetes, hypertension, periph-
eral arterial disease, coronary artery disease, permanent
AF, chronic lung disease, previous myocardial infarction,
previous percutaneous coronary intervention (PCI), previ-
ous cardiac surgery, New York Heart Association
(NYHA) class III or more, lower preoperative estimated
glomerular filtration rate, and pulmonary artery hyperten-
sion. Previous PCI and previous cardiac surgery were
excluded from the multivariable analyses because of their
association with previous myocardial infarction. The vari-
ables of relevance were similar in the subgroup analyses,
except that in the analysis excluding patients who died
within 30 days, the variable previous cardiac surgery did
not reach the P value< .10 required for the multivariable
analysis. In addition, in the analysis of the mortality of pa-
tients with moderate PPS, previous myocardial infarction
and previous cardiac surgery were discarded and active
smoking and previous venous thromboembolism were
added to the model. Survival after isolated SAVR in patients
with severe and moderate PPS separately and in patients
with overall PPS, compared with patients without PPS are
shown in Figure 2 and Figure 3, D. No association was
observed between PPS and all-cause mortality in the overall
study cohort. Analysis excluding patients who died within
30 days after the surgery confirmed these results
(Table 2). However, patients with severe PPS had increased
all-cause mortality (unadjusted analysis: HR, 1.91; 95%CI,
1.01-3.62; P ¼ .046; adjusted analysis: HR, 2.01; 95% CI,
1.03-3.91; P ¼ .040). The difference in mortality of the1450 The Journal of Thoracic and Cardiovascular Sursevere PPS patients appeared within the first 24 months af-
ter the surgery with the median time from the diagnosis to
death being 460 (83-1300) days. The survival of patients
with moderate PPS was similar to that of patients without
PPS (unadjusted analysis: HR, 0.67; 95% CI, 0.36-1.27;
P ¼ .22; adjusted analysis: HR, 0.70; 95% CI, 0.36-1.35;
P ¼ .29).
The underlying cause of death appearing within
24 months after severe PPS diagnosis (n ¼ 7) was often
registered as atherosclerotic heart disease or aortic valve
stenosis. Only 1 patient had PPS registered as the underly-
ing cause of death and 1 as the intermediate cause of death.
The remaining underlying causes of death were single cases
of unspecified sepsis, stroke, and falling in the same level
eventually leading to pneumonia. Pneumonia was regis-
tered as the immediate cause of death in half of the deaths,
including the 2 patients with PPS registered as the underly-
ing or intermediate cause of death. No significant baseline
differences were found between patients who died within
24 months after severe PPS and patients without severe
PPS except that the patients who died within 24 months af-
ter severe PPS had more previous myocardial infarction (2
[29%] vs 30 [4.6%]; P ¼ .042). Preoperative echocardio-
graphic data were available in 6 of 7 patients who died
within 24 months after severe PPS diagnosis and in 599
of 647 of patients without severe PPS. The comparison of
the 2 groups revealed no significant differences in preoper-
ative aortic valve maximum or mean pressure gradient,
aortic valve regurgitation degree, or mitral valve regurgita-
tion degree. However, the patients who died within
24 months after severe PPS had lower preoperative left ven-
tricular ejection fraction compared with patients without se-
vere PPS (median, 48 [43-50]% vs 61 [51-70]%; P¼ .014).
When patients who died within 24 months after the surgery
with and without severe PPS were compared, no significant
differences were found in preoperative left ventricular ejec-
tion fraction (48 [43-50]% vs 61 [45-73]%; P ¼ .116) or
previous myocardial infarction (2 [29%] vs 4 [8.0%];
P ¼ .15).
PPS and Other Adverse Outcomes
During the follow-up, a total of 190 (35.3%) patients
developed new-onset AF after hospital discharge, 62
(9.2%) suffered a major stroke, 111 (16.5%) stroke or
TIA, and 107 (17.2%) developed major bleeding. The
following were the variables of relevance with a P
value< .10 in the univariable analyses of new-onset AF:
increasing age, male sex, greater body mass index, dyslipi-
demia, hypertension, chronic lung disease, active or previ-
ous smoking, previous stroke, previous myocardial
infarction, NYHA class III or higher, lower preoperative
estimated glomerular filtration rate, previous endocarditis,
and pulmonary artery hypertension. Similarly, the
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FIGURE 2. Survival after isolated surgical aortic valve replacement in patients with moderate postpericardiotomy syndrome (PPS; ie, PPS not requiring
the evacuation of pleural or pericardial effusion), patients with severe PPS (ie, PPS requiring the evacuation of pleural or pericardial effusion), and patients
without PPS. Severe PPS seemed to be associated with higher rates of mortality, whereas patients with moderate PPS shared similar prognosis with patients
without PPS.






stroke rate and entered to the multivariable model:
increasing age, diabetes, hypertension, paroxysmal AF, per-
manent AF, chronic lung disease, peripheral arterial dis-
ease, and NYHA class III or higher. The following were
the variables of relevance with a P value< .10 in the uni-
variable analyses of stroke or TIA: increasing age, diabetes,
hypertension, paroxysmal AF, permanent AF, chronic lung
disease, peripheral arterial disease, heavy alcohol consump-
tion, previous stroke, and NYHA class III or higher. Last,
the following variables were associated with higher
bleeding rate and entered to the multivariable model:
younger age, paroxysmal AF, permanent AF, heavy alcohol
consumption, previous PCI, previous cardiac surgery, and
pulmonary artery hypertension. The Cox proportional haz-
ards univariable models and multivariable adjusted Cox
regression models of the effect of PPS on adverse outcomes
are detailed in Table 2. PPS had no significant effect on
these adverse outcomes (Figures 3 and 4), apart from
new-onset AF in the multivariable analysis. As depicted
in Figure 4, this effect appeared within 1 month after the
surgery. When AF episodes during the index hospitalization
were also included, no significant difference in the inci-
dence of new-onset AF was found between patients with
and without PPS (HR, 1.17; 95% CI, 0.83-1.63; P ¼ .37).
Severe PPS was not associated with the higher occurrence
of new-onset AF after hospital discharge (HR, 1.23; 95%
CI, 0.55-2.78; P ¼ .61), major stroke (HR, 0.61; 95% CI,
0.09-4.44; P ¼ .63), stroke or TIA (HR, 0.34; 95% CI,The Journal of Thoracic and Car0.05-2.46; P ¼ .29), or major bleeding (HR, 1.67; 95%
CI, 0.61-4.54; P ¼ .32).
DISCUSSION
Main Findings
The main findings of the present study are as follows. (1)
The higher mortality of PPS patients seems to relate only to
the patients who require invasive interventions because of
the syndrome, and (2) PPS requiring medical attention—
either in moderate or severe form—had a significant tran-
sient effect on the occurrence of new-onset AF during the
early postoperative period, but it did not increase major
stroke, stroke or TIA, or major bleeds during long-term
follow-up, indicating that the higher mortality risk is attrib-
uted to other than these outcomes.
Mortality
Strikingly, severe PPS resulted in a twofold mortality
risk. In contrast, the survival of patients with moderate
PPS was similar to that of patients without PPS. The effect
of PPS on mortality is illustrated in Figure 5. The higher
mortality rate associated with PPS was first reported in a
recent large epidemiological study,7 but the reasons for
this finding remained unknown. Because of the delay of
several months between PPS diagnosis and death, the higher
mortality rate has been presumed to be related to the under-
lying immunological changes caused by or resulting in
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FIGURE 3. Freedom from (A) major stroke, (B) stroke and transient ischemic attack (TIA), (C) major bleeding, and (D) death in patients with (PPSþ) and
without (PPS) PPS. PPS requiring medical attention had no significant effect on the occurrence of these adverse events during long-term follow-up. PPS,
Postpericardiotomy syndrome.




and death varied from weeks to years with a median of
15 months, and the deaths associated with severe PPS
took place within 24 months after the syndrome
(Figure 2). Considering the causes of death, the higher mor-
tality is most likely caused by the incremental disease
burden of PPS and its sequelae, and especially the required
interventions. Therefore, in the light of the present results, it
is unlikely that PPS itself is the cause of incremental deaths
after cardiac surgery. Instead, PPS is likely to complicate
previously weak and vulnerable patients, thus increasing1452 The Journal of Thoracic and Cardiovascular Surmortality with a delay. This hypothesis is supported by
the fact that the patients who died within 24 months after se-
vere PPS had somewhat more previous myocardial infarc-
tions and lower preoperative ejection fraction. However,
although the relationship with the underlying immunolog-
ical changes related to PPS seems unlikely, further studies
are needed to rule it out completely.
Currently, none of the PPS treatments have been shown to
reduce postoperative mortality in previous studies. Never-
theless, none of the studies have been powered togery c December 2020
TABLE 2. The association of PPS with adverse outcomes after isolated surgical aortic valve replacement
Univariable analysis (PPS vs no PPS) Multivariable analysis (PPS vs no PPS)
HR (95% CI) P value HR (95% CI) P value
AF new onset 1.46 (0.97-2.19) .072 1.72 (1.12-2.63) .012
Major stroke 0.45 (0.14-1.43) .17 0.46 (0.14-1.50) .20
Stroke or TIA 0.60 (0.28-1.29) .19 0.63 (0.29-1.37) .25
Major bleeding 0.95 (0.49-1.82) .87 1.02 (0.53-1.98) .94
Death 0.98 (0.62-1.56) .95 1.03 (0.64-1.67) .89
Death (alive after 30 d) 1.06 (0.65-1.73) .82 1.07 (0.64-1.79) .79
PPS, Postpericardiotomy syndrome; HR, hazard ratio; CI, confidence interval; AF, atrial fibrillation; TIA, transient ischemic attack.






investigate the possible mortality benefits of the treatments
in either the preventive use or the management of PPS.
Therefore, it is possible that, for example, the preventive
use of colchicine or more aggressive first-line treatment
of PPS would reduce postoperative mortality if studied in
an adequately sized research setting. Until further knowl-
edge of the possible mortality benefits of the treatment op-
tions is achieved, the best course of action is to provide
more intensive follow-up and treatment of the PPS patients
who require invasive interventions.
PPS and Other Adverse Outcomes
PPS was not associated with major stroke, stroke or TIA,
or major bleeding. However, we found a significant associ-
ation between PPS and the occurrence of new-onset AF. The
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FIGURE 4. Cumulative occurrence of new-onset AF in patients with (PPSþ) a
difference appeared during the first months after the surgery. AF, Atrial fibrilla
The Journal of Thoracic and Carthe initial hospital discharge (Figure 4). Thus, it is possible
that the pericardial irritation caused by PPS provoked AF
paroxysms during the first months after the surgery. In
that case, the effect is most likely transient, and therefore,
it should not affect the overall prognosis of the patients.
In fact, of the PPS patients who developed new-onset AF af-
ter hospital discharge within the first 60 postoperative days
(n¼ 19), only 3 died during the follow-up and the delay be-
tween the operation and death was 3.5 to 5.3 years.
Risk Factors for PPS
In this study, pneumonia during index hospitalization was
associated with PPS. In only 1 previous PPS study the inci-
dence of pneumonia during the early postoperative period
has been reported.12 In the aforementioned study on pa-
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FIGURE 5. Patients with severe PPS (ie, PPS requiring the evacuation of pleural or pericardial effusion) are at increased rates of mortality during the first
24 months after cardiac surgery, whereas patients with mild to moderate PPS and no PPS present equal mortality rates. PPS, Postpericardiotomy syndrome.




grafting, those who developed pneumonia had a trend of
higher incidence of PPS (5.7% vs 3.4%; P ¼ .39). In the
present study, the PPS diagnosis after pneumonia during
the index hospitalization were typically set within 1 week
after hospital discharge. Thus, it is possible that some of
the pneumonia were actually early stages of PPS, because
pneumonia is one of the most difficult differential diagnoses
of PPS during the early postoperative period. This under-
lines the complexity of diagnosing PPS during the early
postoperative period in real life. PPS also typically results
in hypoventilation via pleural irritation and pleural effusion,
which might expose the patients to the development of
pneumonia. However, another possible explanation is that
pneumonia causes an immunological activation that ex-
poses the patients to the development of PPS.
Surprisingly, male sex was associated with higher rates
of occurrence of PPS. In previous studies, female sex and
younger age have been reported as predisposing factors
for PPS.2,13,14 Male patients with PPS were, however,1454 The Journal of Thoracic and Cardiovascular Sursignificantly younger compared with their female coun-
terparts, although the interaction analysis showed no sig-
nificant interactions between age groups and sex. Both of
the previous studies that reported female sex as a risk
factor for PPS have included all cardiac surgery types.2,14
Besides the multiplicity caused by the variety of proced-
ure types, this results in a markedly wider age distribu-
tion compared with the cohort in the present study.
Regardless of the negative result in the interaction anal-
ysis, it is possible that the effect of male sex is indirect
and due to differences in the age distributions of PPS pa-
tients in combination with the differences in procedure
types. This hypothesis is strengthened by the fact that
only 1.0% of the female patients who underwent surgery
were 40 to 49 years of age, which, according to the pre-
vious epidemiological study, is the group with the highest
difference in PPS occurrence between sexes.14 Neverthe-
less, further studies are needed to achieve a definitive
explanation for this finding.gery c December 2020
VIDEO 1. Lead author Joonas Lehto explains the key message of the
article. Video available at: https://www.jtcvs.org/article/S0022-5223(20)
30231-2/fulltext.






In the present study, PPS patients were most often treated
with corticosteroids, although they are no longer recom-
mended because of their association with higher recurrence
rates.10 However, a large part of the treatment was initiated
before the release of the guidelines that recommended not to
use corticosteroids as the first-line treatment. Furthermore,
the studies that reported the high efficiency of colchicine in
the treatment of pericarditis and PPS were mostly published
after most of the patients had already undergone the surgery,
and all of the patients were receiving vitamin K antagonist
treatment, favoring the use of glucocorticoids instead of
high-dose nonsteroidal anti-inflammatory drugs because
of the high bleeding risk.Clinical Implications
This study has several clinical implications. Patients with
severe PPS seem to be at increased risk for long-term mor-
tality. Mortality, however, did not appear to be related to
ischemic stroke, or major bleeds, but possibly to pneu-
monia. Better knowledge of the adverse events of PPS is
crucial, because they define the acceptable level of costs
and possible side effects of prophylactic methods used. In
linewith the present results, in a recent study, PPS was asso-
ciated with all-cause mortality.7 Prevention of death re-
quires more detailed information on which PPS patients
are at the highest risk. Eventually, this might allow the tar-
geting of possible prophylactic methods and/or effective
management options to the patients at the highest risk of
death. As pointed out in a previous study, most of the PPS
diagnoses reported in earlier prospective studies have
been clinically irrelevant.12 The higher mortality rate in se-
vere PPS patients supports the view that severe PPS should
be considered as an end point in future clinical trials. InThe Journal of Thoracic and Caraddition, besides future research, the classification of PPS
into subgroups (moderate and severe) might be useful in
the treatment of PPS patients, because it seems to reflect
the prognosis of the patients.
Strengths and Limitations
CAREBANK is a prospective study focused on the
adverse events after cardiac surgery. Besides the prospec-
tive nature of the database, another strength concerning
both of the databases is that a validated, structured case
report form was used in data collection. As a quality control
of the multicenter CAREAVR database, a professional third
party monitored the data. Furthermore, to the authors’
knowledge, this is the first study to address the possible
adverse events of PPS in a long-term follow-up of several
years. The main limitation of this study is the retrospective
nature of the CAREAVR data. However, data were obtained
from electronic patient records, and data on baseline, oper-
ation, and outcomes are reported in detail at each of the
participating hospitals. Also, the follow-up was complete
for as much as 99.7% of the patients because the treatment
of patients belonging to the catchment areas of the partici-
pating institutions is mainly centralized. This allowed us to
obtain information on major clinical events requiring hospi-
tal treatment and information on outpatient visits after the
surgery because they were performed almost exclusively
in tertiary health care. Data on late mortality were obtained
from Statistics Finland, which ensures the quality of sur-
vival data of the patients. The small size is another limita-
tion of this analysis, and therefore, these findings should
be viewed as hypothesis-generating. The preoperative echo-
cardiographic data were not available in all patients, and
therefore, these factors that possibly affect mortality could
not be included in the multivariable analyses. Also, all tests
leading to the diagnosis of PPS (eg, chest x-ray and echocar-
diography) were not performed regularly to all patients (eg,
on a weekly basis), so the underdiagnosing of asymptomatic
PPS is conceivable. Nevertheless, the tests were performed
as clinically indicated, which reflects the ‘‘real-world’’
feature of the present study.
CONCLUSIONS
The present study suggests that PPS requiring medical
attention increases the occurrence of new-onset AF during
the early postoperative period but has no effect on major
stroke, stroke or TIA, or major bleeding during long-term
follow-up. However, severe PPS seems to be the subgroup
from which the higher mortality of PPS patients is origi-
nated, suggesting that these patients are in the need of
more intensive follow-up and treatment (Video 1).
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